New Three-Drug cocktail targets tough leukemia
NCT ID NCT06454409
First seen Nov 19, 2025 · Last updated May 17, 2026 · Updated 20 times
Summary
This early-stage trial tests whether adding regorafenib to the standard venetoclax plus azacitidine regimen is safe and effective for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. About 20 participants will receive the combination to find the best dose and check for side effects. The goal is to control the disease, not cure it, as ongoing management is expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.